03:25 PM EDT, 09/13/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration.

The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the blood when administered subcutaneously, and a safety and efficacy profiles on par with the intravenous formulation for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

The company's shares were up over 2% in recent trading.

Price: 61.95, Change: +1.41, Percent Change: +2.33